PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Highlights the firm's ability to meet near-term obligations and cover interest expenses. For conservative value investors, strong liquidity and coverage metrics are critical to avoid distress or forced dilution.
0.87
Current Ratio below 0.5x Medical - Pharmaceuticals median of 1.96. Jim Chanos might see a looming risk of liquidity crunch.
0.42
Quick Ratio below 0.5x Medical - Pharmaceuticals median of 1.62. Jim Chanos might see a liquidity gap if the firm cannot tap more credit swiftly.
0.36
Cash Ratio 0.75–0.9x Medical - Pharmaceuticals median of 0.45. John Neff could push for improved balance sheet strength.
69.59
Coverage exceeding 1.5x Medical - Pharmaceuticals median of 0.64. Joel Greenblatt might see near immunity to interest shocks.
0.72
Short-term coverage of 0.72 versus zero Medical - Pharmaceuticals median. Walter Schloss would verify if our cash flow management provides advantages.